|Bid||0.00 x 2200|
|Ask||0.00 x 900|
|Day's range||24.29 - 25.05|
|52-week range||24.29 - 74.75|
|Beta (3Y monthly)||0.53|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Ocular (OCUL) clinches the FDA approval for the label expansion of Dextenza to treat ocular inflammation following ophthalmic surgery.
Anyone researching Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) might want to consider the historical volatility of the...
Ocular's (OCUL) phase III study on OTX-TP for the reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma fails to achieve primary endpoint.
Aerie (AERI) delivered earnings and revenue surprises of 14.29% and -14.27%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The North Carolina, North Carolina-based company said it had a loss of $1.06 per share. Losses, adjusted for non-recurring costs, came to 78 cents per share. The results exceeded Wall Street expectations. ...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak perf...
Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Aerie (AERI) begins dosing in a phase II study on netarsudil ophthalmic solution in Japan for curbing high intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Shares Up.
Aerie (AERI) gets FDA approval for Rocklatan to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension and announces its 2019 revenue and cash burn outlook.
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But when you pick aRead More...
Aerie Pharmaceuticals has moved higher as of late, but there could definitely be trouble on the horizon for this company.
Aerie's (AERI) Investigational New Drug Application for AR-1105 for the treatment of macular edema due to retinal vein occlusion is accepted by the FDA. The candidate will now enter clinical studies.
I've been keeping an eye on Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) because I'm attracted to its fundamentals. Looking at the company as a whole, as a potential stock investment, I believe Read More...
Aerie (AERI) announces encouraging top-line results from its pilot phase II study of netarsudil ophthalmic solution in a Japan.
Aerie Pharmaceuticals (AERI) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Aerie Pharmaceuticals, Inc. (AERI) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Aerie's (AERI) Q3 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.